Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Eliminating hepatitis

Hepatitis awareness

Friday 28 July marks the World Health Organization's (WHO) World Hepatitis Day — an opportunity "to add momentum to all efforts to all efforts to implement the WHO's global health sector strategy on hepatitis for 2016–2021 and help countries achieve the final goal — to eliminate hepatitis." Read The Pharmaceutical Journal's special report on tackling this group of diseases.

Close up of blood spot test board

Hepatitis C and the potential for care delivery in community pharmacySubscription

By ,

Community pharmacists are uniquely placed to deliver hepatitis C virus testing and treatment, and could help efforts in reaching the World Health Organization target for elimination of the disease by 2030.

Transmission Electron Micrograph view (TEM) of Hepatitis B virus

An update on the management of chronic hepatitis B and C infectionSubscription

By , , , ,

Chronic hepatitis B and C infection are leading causes of liver-related morbidity and mortality worldwide. Current therapies for chronic hepatitis B virus (HBV) infection consisting of nucleos(t)ide analogues (NA) rarely lead to functional cure. With a better understanding of the HBV lifecycle, novel agents have been developed with the hope of achieving functional cure. The development of direct-acting antivirals (DAAs) for hepatitis C virus (HCV) therapy has led to ...

Marc Bulterys, team leader of the global hepatitis programme (GHP) at the World Health Organization (WHO)

World Health Organization looks to eliminate threat of hepatitis B and CSubscription

By

The World Health Organization’s Marc Bulterys on the agency’s efforts to eliminate viral hepatitis by scaling up screening and improving access to new and effective drugs

Micrograph of cirrhosis of the liver

Statins benefit patients with hepatitis B and C-related cirrhosis

Statins may benefit patients with cirrhosis of the liver caused by the Hepatitis B (HBV) or Hepatitis C (HCV) virus, according to the results of a Taiwan study published in Hepatology[1] (online, 20 March 2017).

Winners of the 2015 Care Awards Audience Choice Awards. From left, Ryan Buchanan, Pembe Hassan-Hicks and Kevin Noble

Community pharmacy helps diagnose people with hepatitis C infection, study shows

By

Community pharmacists have the potential to identify people with undiagnosed hepatitis C infection, according to research published in Clinical Pharmacist.

Close-up of a person taking a dry-blood spot test

Integrating community pharmacy testing for hepatitis C with specialist careSubscription

By , Pembe Hassan-Hicks, Kevin Noble, Leonie Grellier, Julie Parkes, Salim I Khakoo

Many patients with hepatitis C virus (HCV) infection lie undiagnosed and a significant proportion of patients that have been identified are disengaged from specialist services. The Isle of Wight (IOW) typifies this issue, with an estimated 200 undiagnosed patients with HCV infection and a small number of known cases engaged with specialist services. Aim: To reduce the burden of undiagnosed HCV on the IOW and link new diagnoses directly ...

More on hepatitis

Illustration of hepatitis c virus

Community pharmacies ideally placed to help the global fight against hepatitis C Subscription

2016 brought with it the first fall in deaths from hepatitis C in the UK in more than a decade, likely the result of increased treatment with new direct acting antiviral drugs

Hepatitis C virions micrograph

Reducing hepatitis C virus transmissionSubscription

Combined needle provision and opioid substitution therapy could cut hepatitis C virus transmission risk.

Blood transfusion

Downing Street announces full inquiry into contaminated blood scandal

A full statutory public inquiry will be held to examine how thousands of people were given contaminated blood transfusions during the 1970s and 1980s.

Transmission Electron Micrograph view (TEM) of Hepatitis B virus

An update on the management of chronic hepatitis B and C infectionSubscription

By , , , ,

Chronic hepatitis B and C infection are leading causes of liver-related morbidity and mortality worldwide. Current therapies for chronic hepatitis B virus (HBV) infection consisting of nucleos(t)ide analogues (NA) rarely lead to functional cure. With a better understanding of the HBV lifecycle, novel agents have been developed with the hope of achieving functional cure. The development of direct-acting antivirals (DAAs) for hepatitis C virus (HCV) therapy has led to ...

Marc Bulterys, team leader of the global hepatitis programme (GHP) at the World Health Organization (WHO)

World Health Organization looks to eliminate threat of hepatitis B and CSubscription

By

The World Health Organization’s Marc Bulterys on the agency’s efforts to eliminate viral hepatitis by scaling up screening and improving access to new and effective drugs

Hepatitis C virions

Direct-acting antivirals successfully treating hepatitis C, says Public Health England

Public Health England is urging the public to get tested for hepatitis C after its latest figures revealed a fall in deaths from the disease, which it attributed to the introduction of direct-acting antiviral therapy.

combined sofosbuvir treatment for hepatitis C

Combination treatment for hepatitis C approved by FDA

The US Food and Drug Administration (FDA) has approved the use of the combination treatment Vosevi (sofosbuvir, velpatasvir and voxilaprevir) for the treatment of adults with chronic hepatitis C virus (HCV) genotypes 1–6 without cirrhosis or with mild cirrhosis.

Liver transplant, operating room

Antiviral treatment improves outcomes in patients with advanced cirrhosisSubscription

Hepatitis C drug shown to reduce the need for transplant and lower mortality rate in patients with advanced liver disease.

hepatitis c virus test

Cochrane study on direct-acting antivirals is 'fundamentally flawed', says Hepatitis C Trust

The Hepatitis C Trust has criticised a study carried out by the Cochrane Hepato-Biliary Group that cast doubt on the effectiveness of direct-acting antivirals against hepatitis C, saying it is “fundamentally flawed”.

slide showing healthy liver tissue vs cirrhotic liver tissue

Study finds no evidence for clinical effect of direct-acting antivirals against hepatitis C

Direct-acting antivirals for chronic hepatitis C, do not seem to reduce the risk of hepatitis C-related morbidity or all-cause mortality, according to a study carried out by the Cochrane Hepato-Biliary Group.

More on hepatitis

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.

Pharmaceutical Journal Jobs

More jobs